Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 23, Issue 10, Pages 1332-1342
Publisher
Elsevier BV
Online
2022-09-02
DOI
10.1016/s1470-2045(22)00506-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial
- (2021) Yukihide Kanemitsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant chemotherapy can prolong recurrence-free survival but did not influence the type of recurrence or subsequent treatment in patients with colorectal liver metastases
- (2021) Takashi Kokudo et al. SURGERY
- What Goals Do Patients and Oncologists Have When Starting Medical Treatment for Metastatic Lung Cancer?
- (2020) Adinda Mieras et al. Clinical Lung Cancer
- Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
- (2019) F. E. Buisman et al. BMC CANCER
- The Disease-Free Interval Between Resection of Primary Colorectal Malignancy and the Detection of Hepatic Metastases Predicts Disease Recurrence But Not Overall Survival
- (2019) Diederik J. Höppener et al. ANNALS OF SURGICAL ONCOLOGY
- Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology
- (2018) Bruno Kovic et al. JAMA Internal Medicine
- Early Recurrence After Hepatectomy for Colorectal Liver Metastases: What Optimal Definition and What Predictive Factors?
- (2016) Katsunori Imai et al. ONCOLOGIST
- Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial
- (2016) Kiyoshi Hasegawa et al. PLoS One
- Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection
- (2015) Jean M. Butte et al. ANNALS OF SURGICAL ONCOLOGY
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
- (2015) Marc Buyse et al. BIOMETRICAL JOURNAL
- The heterogeneity statistic I2 can be biased in small meta-analyses
- (2015) Paul T von Hippel BMC Medical Research Methodology
- Five Years of Cancer Drug Approvals
- (2015) Sham Mailankody et al. JAMA Oncology
- Discrepancy Between Recurrence-Free Survival and Overall Survival in Patients with Resectable Colorectal Liver Metastases: A Potential Surrogate Endpoint for Time to Surgical Failure
- (2014) Masaru Oba et al. ANNALS OF SURGICAL ONCOLOGY
- Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer
- (2013) Areej El-Jawahri et al. CANCER
- Predictors for Early Recurrence After Hepatectomy for Initially Unresectable Colorectal Liver Metastasis
- (2013) Shinichiro Takahashi et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
- (2013) Bernard Nordlinger et al. LANCET ONCOLOGY
- Comparison of Adjuvant Systemic Chemotherapy With or Without Hepatic Arterial Infusional Chemotherapy After Hepatic Resection for Metastatic Colorectal Cancer
- (2011) Michael G. House et al. ANNALS OF SURGERY
- Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
- (2011) D. Sargent et al. EUROPEAN JOURNAL OF CANCER
- Reputation and Precedent in the Bevacizumab Decision
- (2011) Daniel Carpenter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
- (2009) M. Ychou et al. ANNALS OF ONCOLOGY
- Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set
- (2009) Aimery de Gramont et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More